Skip to Content

Mycamine Approval History

Mycamine (micafungin sodium) is an echinocandin antifungal agent used for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation, for the treatment of esophageal candidiasis and candidemia.

Development History and FDA Approval Process for Mycamine

Jun 24, 2013Approval FDA Approves Pediatric Indication for Astellas' Mycamine (micafungin sodium) for Injection
Jan 23, 2008Approval FDA Approves Additional Indication for Astellas' Mycamine
Mar 16, 2005Approval Mycamine Approved for Candida Infections
Apr 27, 2004Fujisawa Healthcare, Inc. Submits NDA For Mycamine For Treatment Of Esophageal Candidiasis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.